If the criterion for naming the potential partner is the approaching patent cliff then the possibilities widens, a lot:
https://www.biopharmadive.com/news/pharma-patent-cliff-biologic-drugs-humira-keytruda/642660/
this BF in particular is getting on the radar of some US senators for trying to re-cook their patent for their cash cow:
https://www.fiercepharma.com/pharma/sen-warren-urges-us-pto-closely-scrutinize-mercks-patent-efforts-keytruda
Ann: New PAT-DX3 data demonstrates synthetic lethality, page-26
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $832 | 118.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 9479207 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 2715475 | 3 |
View Market Depth
| Last trade - 15.25pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.8¢ |
Change
-0.001 ( 7.14 %) |
||||
| Open | High | Low | Volume | ||
| 0.8¢ | 0.8¢ | 0.8¢ | 248836 | ||
| Last updated 12.47pm 30/05/2024 ? | |||||
| PAB (ASX) Chart |